The Korea Checkup Tests That Have to Justify Themselves
Seoul sells screening the way other cities sell watches. The tiers are named, the brochures are beautiful, and every step up the price ladder adds a machine. What the brochures do not do is separate the tests with mortality evidence behind them from the tests that mostly generate findings — and Korea, uniquely, has published the data that makes the separation possible. It ran the experiment on its own population.
Part of our hub: Health Checkup in Korea for Foreigners (2026)
This is the first of four parts on buying a Korean comprehensive checkup as a foreign visitor. It is about what to buy. The price ladder itself we covered separately.
The Korea checkup series
Part 1 — The tests that have to justify themselves (you are here)
Part 2 — Booking it yourself, with no one in the middle
Figure 5 from the guide, and one of the pages reproduced in full in the free sample. Every test shown is wrong more often than right when applied to people without symptoms.
The experiment Korea ran on itself
Seoul’s premium tiers are sold on the machines. The evidence for each machine is sold separately.
Korea launched its national cancer screening programme in 1999. Thyroid ultrasound was never part of it — but it was inexpensive to add on at the same visit, and it spread anyway. What happened next was measured carefully and published in the New England Journal of Medicine.
Figure 7 from the Seoul Cut Medical Checkup Guide 2026. Sources: Ahn, Kim & Welch, NEJM 2014; Korea Central Cancer Registry.
Incidence rose fifteen-fold. Deaths did not move at all. Regional screening prevalence tracked regional incidence at r = 0.75. An IARC analysis in the same journal later estimated that roughly nine in ten thyroid cancers diagnosed in Korean women in that era were overdiagnosis — real cancers, correctly identified by a pathologist, that would never have caused symptoms in that person's lifetime.
What overdiagnosis is not
It is not a misdiagnosis and it is not a false positive. The tumour is there. Autopsy series find papillary thyroid carcinoma in about one in nine thyroid glands of people who died of something else. Look hard enough with a good enough machine and you will find one. The question a screening buyer has to answer is what happens next.
What the finding costs the person it is found in
A nodule found is a nodule biopsied, and a biopsy that reads as carcinoma is, in most systems, an operation.
A nodule found is a nodule biopsied, and a biopsy that reads as carcinoma is, in most systems, an operation. The Korean surgical series that followed this period is large enough to be reliable.
Two facts settle the argument about whether this is a fringe view. Korea's own National Cancer Screening Program funds screening for stomach, liver, colorectal, breast and cervical cancer, with lung screening added for high-risk smokers. Thyroid is not on the list. The government does not fund thyroid screening; private centres sell it. And the US Preventive Services Task Force gives thyroid cancer screening in asymptomatic adults a Grade D — recommends against.
In March 2014 a coalition of Korean physicians said this publicly. Within a year thyroid operations fell by about a third and incidence fell with them. Then, from 2016, incidence began climbing again at roughly five per cent a year, and thyroid is once more the most commonly diagnosed cancer in Korea. The correction did not hold.
The question to ask before the machine finds anything
Thyroid ultrasound appears in most Korean premium tiers, frequently without a separate line price. You are not obliged to decline it. But decide in advance, with your own physician, what you would do about a six-millimetre nodule — because that decision is much harder to make calmly once the nodule has a report number attached to it.
Free sample · Seoul Cut Medical Checkup Guide
The full contents list and the first of the twelve correspondence letters, free, in five languages. Seoul Cut is a publisher: no hospital, clinic or agency pays us, and no institution reviewed this before publication.
The brain scan whose finding has no obvious next step
A screening MRA finds an aneurysm in roughly one Korean adult in thirty. What follows is the hard part.
Brain MRI with MRA is the marquee inclusion of the platinum-class tiers. It is a genuinely excellent scan. Here is the arithmetic that comes with it.
Read the second and third rows together. A small anterior aneurysm carries a rupture risk of roughly a tenth of a per cent a year. Repairing it carries a nine to twelve per cent risk of death or disability inside twelve months. Under those numbers the intervention can be two orders of magnitude more dangerous than the finding, and the major guidelines do not support population screening — they reserve it for people with two affected first-degree relatives, polycystic kidney disease, or a prior aneurysmal haemorrhage.
This is not an argument against brain MRA. It is an argument for knowing, before the tier is paid for, that a positive result does not come with an obvious next step attached.
The heart scan two trials could not validate
Two randomised trials tested exactly the proposition this tier is priced on.
Coronary calcium CT is the most commonly sold cardiac test in Seoul screening; it sits in the premium tier of nearly every major centre. Exactly one proposition has been tested at scale — CT-based cardiovascular screening of asymptomatic men — and the larger of the two randomised trials, DANCAVAS, enrolled 46,611 Danish men aged 65 to 74.
That is not a finding that says the scan is useless, and subgroup signals in younger men have kept the question open. It is a finding that says the confident version of the sales pitch — screen the asymptomatic and live longer — has not been demonstrated in the trial designed to demonstrate it. A tier priced on that premise deserves the question.
The number the tiers never print
Every imaging-dense package has a total radiation dose. No brochure we have seen prints it.
Figure 8 from the Seoul Cut Medical Checkup Guide 2026. Sources: RadiologyInfo (RSNA/ACR); Minamimoto, Ann Nucl Med 2013.
Our own arithmetic, labelled as ours and not as a published figure: a flagship tier combining PET-CT, abdominal CT and coronary CT angiography delivers somewhere around 30 to 40 mSv in a single morning — ten to thirteen years of natural background. Bought annually for a decade, that approaches the range in which excess cancer risk is directly observed in epidemiological cohorts rather than modelled.
What this does not mean
It is not an argument to refuse imaging, and it is emphatically not medical advice — this is a consumer guide, not a clinician, and every decision here belongs to you and your own doctor. The practical implication is narrower and duller: do not buy the same high-dose package every single year by default. Ask which components you need annually and which every three to five years. In our experience it is the single highest-value question a buyer can ask.
Korean screening infrastructure is genuinely world-class, and the gastric-cancer outcome data behind it is the strongest argument anyone can make for making this trip. The same infrastructure, sold commercially to buyers who cannot evaluate it, also produced a documented overdiagnosis epidemic that Korean doctors had to intervene against in public. Both things are true. A guide that told you only the first half would be marketing.
The Korea checkup series
Part 1 — The tests that have to justify themselves (you are here)
Part 2 — Booking it yourself, with no one in the middle
Free sample · Seoul Cut Medical Checkup Guide
The full contents list and the first of the twelve correspondence letters, free, in five languages. Seoul Cut is a publisher: no hospital, clinic or agency pays us, and no institution reviewed this before publication.
Sources
Ahn HS, Kim HJ, Welch HG. Korea's thyroid-cancer "epidemic" — screening and overdiagnosis. N Engl J Med 2014
Vaccarella S et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N Engl J Med 2016 (IARC)
US Preventive Services Task Force — screening for thyroid cancer, Grade D recommendation (2017)
National Cancer Center Korea — National Cancer Screening Program, covered cancers
Lindholt JS et al. Five-year outcomes of the Danish Cardiovascular Screening (DANCAVAS) trial. N Engl J Med 2022;387:1385-95
International Study of Unruptured Intracranial Aneurysms (ISUIA) — natural history and treatment risk.
RadiologyInfo.org (RSNA / ACR) — radiation dose in X-ray and CT examinations
Unruptured intracranial aneurysm prevalence, pooled meta-analysis, Neurointervention 2021; Minamimoto R et al. Ann Nucl Med 2013.
